EP2291178A4 - Formulations à libération contrôlée de pramipexole - Google Patents

Formulations à libération contrôlée de pramipexole

Info

Publication number
EP2291178A4
EP2291178A4 EP09763332.5A EP09763332A EP2291178A4 EP 2291178 A4 EP2291178 A4 EP 2291178A4 EP 09763332 A EP09763332 A EP 09763332A EP 2291178 A4 EP2291178 A4 EP 2291178A4
Authority
EP
European Patent Office
Prior art keywords
pramipexole
controlled release
release formulations
formulations
controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09763332.5A
Other languages
German (de)
English (en)
Other versions
EP2291178A2 (fr
Inventor
Michael L Viera
Padmanabh P Bhatt
Austin B Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supernus Pharmaceuticals Inc
Original Assignee
Supernus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supernus Pharmaceuticals Inc filed Critical Supernus Pharmaceuticals Inc
Publication of EP2291178A2 publication Critical patent/EP2291178A2/fr
Publication of EP2291178A4 publication Critical patent/EP2291178A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP09763332.5A 2008-06-09 2009-06-05 Formulations à libération contrôlée de pramipexole Withdrawn EP2291178A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12917508P 2008-06-09 2008-06-09
PCT/US2009/046349 WO2009152041A2 (fr) 2008-06-09 2009-06-05 Formulations à libération contrôlée de pramipexole

Publications (2)

Publication Number Publication Date
EP2291178A2 EP2291178A2 (fr) 2011-03-09
EP2291178A4 true EP2291178A4 (fr) 2013-07-24

Family

ID=41400531

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09763332.5A Withdrawn EP2291178A4 (fr) 2008-06-09 2009-06-05 Formulations à libération contrôlée de pramipexole

Country Status (4)

Country Link
US (1) US20090304794A1 (fr)
EP (1) EP2291178A4 (fr)
CA (1) CA2725482A1 (fr)
WO (1) WO2009152041A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010266285A1 (en) * 2009-07-02 2012-02-09 Supernus Pharmaceuticals, Inc. A method of treatment of a neurological disorder
WO2011128914A2 (fr) 2010-04-15 2011-10-20 Cadila Healthcare Limited Compositions pharmaceutiques de pramipexole à libération prolongée
JP2013526601A (ja) 2010-05-24 2013-06-24 ルピン・リミテッド プラミペキソールの徐放性製剤
KR101307334B1 (ko) * 2010-07-02 2013-09-12 주식회사 바이오파마티스 프라미펙솔 또는 이의 약학적으로 허용되는 염을 포함하는 안정성이 개선된 서방형 약학 조성물
CN102670550A (zh) * 2011-03-14 2012-09-19 北京天衡药物研究院 盐酸普拉克索渗透泵型控释片

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010999A1 (fr) * 2002-07-25 2004-02-05 Pharmacia Corporation Forme posologique a prise unique quotidienne de pramipexole
WO2007090882A2 (fr) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Compositions pharmaceutiques
WO2008001341A1 (fr) * 2006-06-27 2008-01-03 Biovail Laboratories International Srl Système de délivrance osmotique multiparticulaire

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20060177507A1 (en) * 2003-05-22 2006-08-10 Joaquina Faour Controlled release device containing lercanidipine
US20050119249A1 (en) * 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
HRP20100682T4 (hr) * 2004-08-13 2014-08-01 Boehringer Ingelheim International Gmbh Formulacija tablete produljenog oslobađanja koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu sol, postupak njezine priprave i uporaba
KR20070059161A (ko) * 2004-09-21 2007-06-11 산동 루예 파마슈티칼 컴파니 리미티드 도파민 수용체 효능제를 함유하는 장시간 작용 서방성 제제및 그 제조방법
WO2006046256A1 (fr) * 2004-10-27 2006-05-04 Alembic Limited Formulation a liberation prolongee de dihydrochlorure de pramipexole
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
US20070134315A1 (en) * 2005-12-08 2007-06-14 Viera Michael L Orally administrable extended release pellet and tablet formulations of a highly water soluble compound
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010527946A (ja) * 2007-05-25 2010-08-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソールを含有する医薬製剤
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010999A1 (fr) * 2002-07-25 2004-02-05 Pharmacia Corporation Forme posologique a prise unique quotidienne de pramipexole
WO2007090882A2 (fr) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Compositions pharmaceutiques
WO2008001341A1 (fr) * 2006-06-27 2008-01-03 Biovail Laboratories International Srl Système de délivrance osmotique multiparticulaire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WAKODE RAJESHRI ET AL: "Development and evaluation of push-pull based osmotic delivery system for pramipexole", PDA JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, BETHESDA, MD, US, vol. 62, no. 1, 1 January 2008 (2008-01-01), pages 22 - 31, XP002685437, ISSN: 1079-7440 *

Also Published As

Publication number Publication date
WO2009152041A3 (fr) 2010-02-25
CA2725482A1 (fr) 2009-12-17
WO2009152041A2 (fr) 2009-12-17
US20090304794A1 (en) 2009-12-10
EP2291178A2 (fr) 2011-03-09

Similar Documents

Publication Publication Date Title
IL217153A0 (en) Controlled release formulations
ZA201008882B (en) Controlled release of microbiocides
EP2379059A4 (fr) Composition à libération contrôlée
GB0807612D0 (en) New use of surfactant
EP2273880A4 (fr) Compositions inédites destinées au traitement de la migraine
PT2345410T (pt) Composição farmacêutica para libertação modificada
IL214624A0 (en) Controlled release pharmaceutical formulations of nitazoxanide
GB2446944B (en) Removal of prosthesis
IL208481A0 (en) Controlled release of active agents from oleosomes
GB0811024D0 (en) Sustained release treatment of depression
IL212119A0 (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
GB0822000D0 (en) Control of parasites
IL210149A0 (en) Isolation of cyclopamine
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
EP2212251A4 (fr) Procédés de préparation du clusterboron ®
ZA200904939B (en) Extended release formulation of nevirapine
GB0816459D0 (en) State of change estimate
IL206577A0 (en) Formulations of flibanserin
EP2296709A4 (fr) Formulations de niacine à libération modifiée
IL217135A0 (en) Stabilized herbicidal formulations and methods of use
EP2291178A4 (fr) Formulations à libération contrôlée de pramipexole
EP2285219A4 (fr) Formulations à libération contrôlée d alprazolam
EP2252306A4 (fr) Nouvelle utilisation de probiotiques
TWI367205B (en) Preparation of paricalcitol
EP2205524A4 (fr) Procédés de fabrication de bore en grappe

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101209

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130624

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/38 20060101ALI20130618BHEP

Ipc: A61K 9/22 20060101AFI20130618BHEP

Ipc: A61K 47/26 20060101ALI20130618BHEP

Ipc: A61K 9/52 20060101ALI20130618BHEP

Ipc: A61P 25/16 20060101ALI20130618BHEP

Ipc: A61P 25/28 20060101ALI20130618BHEP

Ipc: A61K 31/425 20060101ALI20130618BHEP

111Z Information provided on other rights and legal means of execution

Free format text: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

Effective date: 20140312

17Q First examination report despatched

Effective date: 20140401

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160608